The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease.


Journal

Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795

Informations de publication

Date de publication:
01 2020
Historique:
received: 18 08 2018
accepted: 12 09 2019
pubmed: 4 12 2019
medline: 18 3 2020
entrez: 4 12 2019
Statut: ppublish

Résumé

IgG4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ. Correlation among clinical, serologic, radiologic, and pathologic data is required for diagnosis. This work was undertaken to develop and validate an international set of classification criteria for IgG4-RD. An international multispecialty group of 86 physicians was assembled by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). Investigators used consensus exercises, existing literature, derivation and validation cohorts of 1,879 subjects (1,086 cases, 793 mimickers), and multicriterion decision analysis to identify, weight, and test potential classification criteria. Two independent validation cohorts were included. A 3-step classification process was developed. First, it must be demonstrated that a potential IgG4-RD case has involvement of at least 1 of 11 possible organs in a manner consistent with IgG4-RD. Second, exclusion criteria consisting of a total of 32 clinical, serologic, radiologic, and pathologic items must be applied; the presence of any of these criteria eliminates the patient from IgG4-RD classification. Third, 8 weighted inclusion criteria domains, addressing clinical findings, serologic results, radiology assessments, and pathology interpretations, are applied. In the first validation cohort, a threshold of 20 points had a specificity of 99.2% (95% confidence interval [95% CI] 97.2-99.8%) and a sensitivity of 85.5% (95% CI 81.9-88.5%). In the second, the specificity was 97.8% (95% CI 93.7-99.2%) and the sensitivity was 82.0% (95% CI 77.0-86.1%). The criteria were shown to have robust test characteristics over a wide range of thresholds. ACR/EULAR classification criteria for IgG4-RD have been developed and validated in a large cohort of patients. These criteria demonstrate excellent test performance and should contribute substantially to future clinical, epidemiologic, and basic science investigations.

Identifiants

pubmed: 31793250
doi: 10.1002/art.41120
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7-19

Investigateurs

Takashi Akamizu (T)
Mitsuhiro Akiyama (M)
Lillian Barra (L)
Adrian Bateman (A)
Daniel Blockmans (D)
Pilar Brito-Zeron (P)
Corrado Campochiaro (C)
Mollie Carruthers (M)
Suresh Chari (S)
Tsutomu Chiba (T)
Hyon Choi (H)
Lynn Cornell (L)
Emma Culver (E)
Saman Darabian (S)
Emanuel Della Torre (ED)
Vikram Deshpande (V)
Lingli Dong (L)
Mikael Ebbo (M)
Andreu Fernández-Codina (A)
Judith A Ferry (JA)
George Fragkoulis (G)
Fabian Frost (F)
Luca Frulloni (L)
Phil A Hart (PA)
Gabriela Hernandez-Molina (G)
Dai Inoue (D)
Haihan Ji (H)
Karuna Keat (K)
Terumi Kamisawa (T)
Shigeyuki Kawa (S)
Mitsuhiro Kawano (M)
Arezou Khosroshahi (A)
H Kobayashi (H)
Yuzo Kodama (Y)
Satoshi Kubo (S)
Kensuke Kubota (K)
Marco Lanzillotta (M)
Haiyang Leng (H)
Markus Lerch (M)
Yanying Liu (Y)
Zhifu Liu (Z)
Matthias Löhr (M)
Eduardo Martin-Nares (E)
Ferran Martinez-Valle (F)
Chiara Marvisi (C)
Yasufumi Masaki (Y)
Shoko Matsui (S)
Ichiro Mizushima (I)
Ray P Naden (RP)
Seiji Nakamura (S)
Jan Nordeide (J)
Kenji Notohara (K)
Kazuichi Okazaki (K)
Sergio Paira (S)
Cory A Perugino (CA)
Jovan Popovic (J)
Manel Ramos-Casals (M)
James Rosenbaum (J)
Jay Ryu (J)
Takako Saeki (T)
Yasuharu Sato (Y)
Nicolas Schleinitz (N)
Hiroshi Sekiguchi (H)
Amita Sharma (A)
Evgeniya V Sokol (EV)
James R Stone (JR)
John H Stone (JH)
Wenwu Sun (W)
Hiroki Takahashi (H)
Naoki Takahashi (N)
Masayuki Takahira (M)
Yoshiya Tanaka (Y)
Hisanori Umehara (H)
Augusto Vaglio (A)
Alejandra Villamil (A)
Yoko Wada (Y)
Zachary S Wallace (ZS)
George Webster (G)
Kazunori Yamada (K)
Motohisa Yamamoto (M)
Joanne Yi (J)
Yinlan Yi (Y)
Giuseppe Zamboni (G)
Yoh Zen (Y)
Wen Zhang (W)

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2019, American College of Rheumatology.

Références

Stone JH, Zen Y, Deshpande V. IgG4-related disease [review]. N Engl J Med 2012;366:539-51.
Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease [review]. Lancet 2015;385:1460-71.
Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003;38:982-4.
Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001;344:732-8.
Stone JH, Khosroshahi A, Deshpande V, Chan JK, Heathcote JG, Aalberse R, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum 2012;64:3061-7.
Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kulikova M, Pillai S, et al. IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol 2015;67:2466-75.
Sekiguchi H, Horie R, Kanai M, Suzuki R, Yi ES, Ryu JH. IgG4-related disease: retrospective analysis of one hundred sixty-six patients. Arthritis Rheumatol 2016;68:2290-9.
Kuroda N, Nao T, Fukuhara H, Karashima T, Inoue K, Taniguchi Y, et al. IgG4-related renal disease: clinical and pathological characteristics. Int J Clin Exp Pathol 2014;7:6379-85.
Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012;25:1181-92.
Brito-Zerón P, Bosch X, Ramos-Casals M, Stone JH. IgG4-related disease: advances in the diagnosis and treatment. Best Pract Res Clin Rheumatol 2016;30:261-78.
Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis 2015;74:14-8.
Hao M, Liu M, Fan G, Yang X, Li J. Diagnostic value of serum IgG4 for IgG4-related disease: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2016;95:e3785.
Mahajan VS, Mattoo H, Deshpande V, Pillai SS, Stone JH. IgG4-related disease. Annu Rev Pathol 2014;9:315-47.
Chari ST. Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic's HISORt criteria. J Gastroenterol 2007;42 Suppl 18:39-41.
Perugino CA, Wallace ZS, Meyersohn N, Oliveira G, Stone JR, Stone JH. Large vessel involvement by IgG4-related disease. Medicine (Baltimore) 2016;95:e3344.
Fransen J, Johnson SR, van den Hoogen F, Baron M, Allanore Y, Carreira PE, et al. Items for revised classification criteria in systemic sclerosis: results of a consensus exercise. Arthritis Care Res (Hoboken) 2012;64:351-7.
Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, et al. Use of consensus methodology to determine candidate items for systemic lupus erythematosus classification criteria. J Rheumatol 2019;46:721-6.
Johnson SR, Naden RP, Fransen J, van den Hoogen F, Pope JE, Baron M, et al. Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. J Clin Epidemiol 2014;67:706-14.
Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Dörner T, Diamond B, et al. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019;78:634-40.
Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol 2015;67:2557-68.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737-47.
Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-98.
Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-5.
Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003;56:1129-35.
Classification and Response Criteria Subcommittee of the American College of Rheumatology Committee on Quality Measures. Development of classification and response criteria for rheumatic diseases [editorial]. Arthritis Rheum 2006;55:348-52.
Johnson SR, Goek ON, Singh-Grewal D, Vlad SC, Feldman BM, Felson DT, et al. Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum 2007;57:1119-33.
Dougados M, Gossec L. Classification criteria for rheumatic diseases: why and how? [editorial]. Arthritis Rheum 2007;57:1112-5.
Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, et al. Distinctions between diagnostic and classification criteria? [review]. Arthritis Care Res (Hoboken) 2015;67:891-7.
Felson DT, Anderson JJ. Methodological and statistical approaches to criteria development in rheumatic diseases. Baillieres Clin Rheumatol 1995;9:253-66.
Chari ST, Takahashi N, Levy MJ, Smyrk TC, Clain JE, Pearson RK, et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol 2009;7:1097-103.

Auteurs

Zachary S Wallace (ZS)

Massachusetts General Hospital, Boston.

Ray P Naden (RP)

New Zealand Health Ministry, Auckland, New Zealand.

Suresh Chari (S)

Mayo Clinic, Rochester, Minnesota.

Hyon Choi (H)

Massachusetts General Hospital, Boston.

Emanuel Della-Torre (E)

IRCCS Ospedale San Raffaele, Milan, Italy.

Jean-Francois Dicaire (JF)

Pinnacle, Inc., Montreal, Quebec, Canada.

Phil A Hart (PA)

Ohio State University College of Medicine, Columbus.

Dai Inoue (D)

Kanazawa University, Kanazawa, Japan.

Mitsuhiro Kawano (M)

Kanazawa University Hospital, Kanazawa, Japan.

Arezou Khosroshahi (A)

Emory University, Atlanta, Georgia.

Kensuke Kubota (K)

Yokohama City University, Yokohama, Japan.

Marco Lanzillotta (M)

IRCCS, Milan, Italy.

Kazuichi Okazaki (K)

Kansai Medical University, Hirakata, Japan.

Cory A Perugino (CA)

Massachusetts General Hospital, Boston.

Amita Sharma (A)

Massachusetts General Hospital, Boston.

Takako Saeki (T)

Nagaoka Red Cross Hospital, Nagaoka, Japan.

Hiroshi Sekiguchi (H)

Mayo Clinic, Rochester, Minnesota.

Nicolas Schleinitz (N)

Aix-Marseille University, Marseille, France.

James R Stone (JR)

Massachusetts General Hospital, Boston.

Naoki Takahashi (N)

Mayo Clinic, Rochester, Minnesota.

Hisanori Umehara (H)

Kanazawa Medical University, Uchinada, Japan, and Hayashi Hospital, Echizen, Japan.

George Webster (G)

University College London, London, UK.

Yoh Zen (Y)

Kobe University, Kobe, Japan.

John H Stone (JH)

Massachusetts General Hospital, Boston.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH